No, you do not need a special license to prescribe Suboxone. Since January 2023, any physician, nurse practitioner, or physician assistant with a standard DEA registration that covers Schedule III controlled substances can prescribe buprenorphine products like Suboxone for opioid use disorder, as long as their state license permits it. The old “X-waiver” credential was eliminated by federal law, and the only added obligation is a one-time, eight-hour training on substance use disorders tied to DEA registration.1SAMHSA. Waiver Elimination (MAT Act)
Who Is Federally Eligible to Prescribe Suboxone
Any DEA-registered practitioner whose registration includes Schedule III authority is federally eligible. That means physicians, physician assistants, and nurse practitioners can all write Suboxone prescriptions for opioid use disorder, provided their state license and scope of practice allow it.2U.S. Food and Drug Administration. Primary Care Providers Can Prescribe with Confidence
Before 2023, most primary care providers were shut out of prescribing buprenorphine because they had not completed the separate federal waiver process. That barrier is gone. A regular family doctor, an urgent care clinician, or a nurse practitioner at a community health center can all potentially write the prescription. Addiction specialists remain an option, but they are no longer a requirement.
The Training That Replaced the X-Waiver
The X-waiver was repealed by the Mainstreaming Addiction Treatment (MAT) Act within the Consolidated Appropriations Act of 2023, signed on December 29, 2022.1SAMHSA. Waiver Elimination (MAT Act) Starting June 27, 2023, every practitioner applying for a new DEA registration or renewing an existing one must attest that they have completed eight hours of training on the treatment and management of patients with opioid or other substance use disorders.3U.S. Department of Justice, DEA Diversion Control Division. DEA Registered-Practitioners
The training can come from a range of accredited sources, and many courses are free through federal grants. It applies to all DEA registrants, not only those who plan to prescribe buprenorphine, and it is built into the standard registration process rather than existing as a separate credential. A practitioner who does not complete it cannot renew or obtain a DEA registration at all.
Some practitioners are treated as already meeting the requirement:
- Board-certified addiction specialists holding certification in addiction medicine or addiction psychiatry from the American Board of Medical Specialties, the American Board of Addiction Medicine, or the American Osteopathic Association.3U.S. Department of Justice, DEA Diversion Control Division. DEA Registered-Practitioners
- Recent graduates who finished a medical, dental, physician assistant, or advanced practice nursing program in good standing within five years of June 27, 2023, if the curriculum included at least eight hours of substance use disorder training.
- Practitioners who previously completed the DATA-waiver training already satisfy the new requirement.
Patient Caps and Pharmacist Verification Are Gone
Under the old system, waivered providers were limited in how many patients they could treat at once, with tiered ceilings of 30, 100, and 275.4Drug Enforcement Administration. Elimination of Patient Limits for Prescribing Buprenorphine Federal law now places no limit on the number of patients a practitioner can treat with buprenorphine for opioid use disorder. A provider can treat as many patients as they can safely manage within their clinical judgment and state regulations.
The X-number itself is also gone. Pharmacists filling a buprenorphine prescription for opioid use disorder no longer need to verify a special waiver number; they simply confirm the prescription comes from a practitioner with a valid, standard DEA registration.5SAMHSA. Pharmacist Verification of Buprenorphine Providers If a pharmacy declines to fill a buprenorphine prescription by citing an X-waiver requirement, the regulation no longer supports that.
State Rules Still Apply
Federal law removed the X-waiver, but it did not override state-level rules. Every practitioner must comply with both federal and state requirements, and state medical, nursing, and pharmacy boards can impose their own conditions on buprenorphine prescribing. These can include state-level controlled substance registrations, additional training beyond the federal eight hours, and specific practice guidelines around counseling or dosing.
Scope-of-practice laws matter especially for nurse practitioners and physician assistants. Some states require them to operate under a collaborative agreement with a physician for controlled substances, and a few have imposed stricter conditions specifically for buprenorphine, such as requiring the collaborating physician to have experience in addiction treatment. These rules change frequently, so NPs and PAs should check with their state licensing board before prescribing.
Most states also require practitioners to check the state Prescription Drug Monitoring Program before writing a controlled substance prescription, including buprenorphine. Timing and frequency vary, but the obligation is nearly universal.
Counseling Is Not a Precondition for Prescribing
A common misconception is that Suboxone can only be prescribed alongside mandatory counseling or behavioral health services. The FDA addressed this directly in a 2023 letter: counseling should always be offered, but a provider should not withhold buprenorphine because a patient has not yet connected with counseling or behavioral health services.6U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Letter Regarding Buprenorphine Treatment for OUD Given the risk of fatal overdose without medication, stabilizing the patient on buprenorphine takes priority.
Federal regulations governing opioid treatment programs reinforce the same approach: a patient’s refusal of counseling cannot be used as a reason to deny them medication for opioid use disorder.7Federal Register. Medications for the Treatment of Opioid Use Disorder If a clinic requires therapy before writing a Suboxone prescription, that is a clinic policy choice, not a federal requirement.
Prescribing Suboxone Through Telehealth in 2026
The Ryan Haight Act normally requires at least one in-person evaluation before a practitioner can prescribe a controlled substance remotely. Two overlapping federal authorities currently waive that requirement for buprenorphine.
A permanent DEA rule effective February 18, 2025 allows practitioners to initiate buprenorphine treatment for opioid use disorder via telemedicine, including audio-only calls, without a prior in-person visit. The prescriber must review the patient’s state PDMP data before issuing the prescription and document the date and time of that review. Initial prescriptions under this pathway are limited to a six-month period from the date the first prescription is issued, after which the practitioner must either see the patient in person or continue treatment through another qualifying telemedicine arrangement.8Federal Register. Expansion of Buprenorphine Treatment via Telemedicine Encounter
Separately, the DEA has extended broader COVID-era telemedicine flexibilities through December 31, 2026. Under that temporary extension, DEA-registered practitioners can prescribe Schedule II through V controlled substances via telemedicine without ever having conducted an in-person evaluation, subject to federal and state law.9Federal Register. Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities After December 31, 2026, the temporary flexibilities expire unless Congress or the DEA acts again, and the permanent rule’s PDMP-check and six-month initial prescribing window will become the main pathway for new telehealth patients.
Compliance Duties That Come With Prescribing
Even without a special license, prescribing Suboxone carries the same record-keeping and compliance duties that apply to any Schedule III controlled substance. Every prescription must be issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice.10U.S. Department of Justice, Diversion Control Division. Buprenorphine (MOUD) Q&A Federal regulations require controlled substance records to be maintained for at least two years; many state boards require seven years or longer.
For telehealth prescribers, the documentation requirements are more detailed. Each prescription must include the standard information (patient name and address, drug name, strength, quantity, directions, and the practitioner’s DEA number), and the provider must annotate the date and time of the PDMP review in the patient’s health record. If the PDMP was inaccessible, the record must show the date, time, and reason the data could not be reviewed, and the prescription is limited to a seven-day supply until the PDMP becomes available.8Federal Register. Expansion of Buprenorphine Treatment via Telemedicine Encounter
So the shortest answer to the licensing question stands: a standard DEA registration with Schedule III authority, a state license that permits controlled substance prescribing, and the one-time eight-hour training attested at DEA registration or renewal. Nothing more specific to Suboxone is required at the federal level.